Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
5.56 | 9.60 | — | — |
+8 more quarters Free account |
P/S ratio |
7.05 | 8.46 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
165.34 | (52.35) | — | — | |
P/B ratio |
0.00 | 0.00 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
6.87 | 8.67 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(9.73) | (8.21) | — | — | |
EV/FCF |
(9.72) | (8.20) | — | — | |
Quick Ratio |
1.61 | 2.48 | 2.34 | 0.53 | |
Current Ratio |
1.95 | 3.03 | 2.76 | 0.89 | |
Net Debt/EBITDA |
(20.37) | (0.10) | (1.91) | (5.37) | |
Debt/Assets |
33.90% | 47.82% | 69.28% | 95.09% | |
Debt/Equity |
(1.89) | (2.16) | (1.86) | (0.80) | |
Asset Turnover |
0.40 | 0.34 | 0.00 | 0.00 | |
Operating CF/Net income |
0.31 | (0.26) | (0.46) | 0.60 | |
Capex/Depreciation |
(0.03) | 0.00 | 0.00 | (0.05) | |
Interest Coverage |
0.01 | (2.96) | (3.33) | 1.98 | |
Research and Development Expense of Revenue |
48.36% | 135.02% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
48.58% | 135.14% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.68% | 19.09% | 0.00% | 0.00% | |
Graham Net Nets |
(0.22) | (0.22) | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
17.98% | 10.42% | — | — | |
Free Cash Flow Yield |
(10.02%) | (12.49%) | — | — | |
Revenue per Share |
0.40 | 0.14 | 0.00 | 0.00 | |
Operating CF per Share |
0.06 | (0.20) | (0.63) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.06 | (0.20) | (0.63) | (0.28) | |
Cash per Share |
1.83 | 1.88 | 2.71 | 0.54 | |
Shareholders Equity per Share |
(0.71) | (0.88) | (1.91) | (3.33) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.71) | (0.88) | (1.91) | (3.33) | |
Free Cash Flow |
4.10 | (14.51) | (39.84) | (18.48) | |
Working Capital |
90.28 | 120.91 | 137.61 | (8.95) | |
Capital Expenditures |
(0.04) | — | 0.00 | (0.01) | |
Net Current Asset Value |
(152.94) | (169.15) | (231.20) | (334.38) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
13.79 | 9.55 | 9.33 | 6.65 | |
Average Payables |
7.59 | 4.89 | 5.33 | 10.11 | |
Average Inventory |
1.02 | 0.77 | — | — | |
Average Assets |
243.70 | 260.67 | 301.36 | 249.52 | |
Average Common Equity |
(140.02) | (138.44) | (151.92) | (187.32) |
Columns are period end dates